Karsten E. Weber
About
Karsten E. Weber is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Karsten E. Weber has authored 44 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Cancer Research, 22 papers in Oncology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Karsten E. Weber's work include Breast Cancer Treatment Studies (17 papers), Cancer Genomics and Diagnostics (13 papers) and Advanced Breast Cancer Therapies (9 papers). Karsten E. Weber is often cited by papers focused on Breast Cancer Treatment Studies (17 papers), Cancer Genomics and Diagnostics (13 papers) and Advanced Breast Cancer Therapies (9 papers). Karsten E. Weber collaborates with scholars based in Germany, Austria and United States. Karsten E. Weber's co-authors include Ralf Kronenwett, Christoph Petry, Jan C. Brase, Carsten Denkert, Sibylle Loibl, Martin Filipits, Peter Dubsky, Marcus Schmidt, Elmar Stickeler and Margaretha Rudas and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.
In The Last Decade
Karsten E. Weber
42 papers receiving 1.1k citations
Peers
Karsten E. Weber
Matthew D. Burstein United States
Zakaria Einbeigi Sweden
Ida Minchella Italy
Farhat Ben Ayed Tunisia
Giorgio Mustacchi Italy
Rutger H.T. Koornstra Netherlands
Yidong Zhou China
Mireia Margelí Vila Spain
Gian Luigi Cetto Italy
Chiu-Kit Tse United States
Citations per year, relative to Karsten E. Weber Karsten E. Weber (= 1×)
peers
Matthew D. Burstein
Countries citing papers authored by Karsten E. Weber
Since
Specialization
Citations
This map shows the geographic impact of Karsten E. Weber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karsten E. Weber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karsten E. Weber more than expected).
Fields of papers citing papers by Karsten E. Weber
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Karsten E. Weber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karsten E. Weber. The network helps show where Karsten E. Weber may publish in the future.
Co-authorship network of co-authors of Karsten E. Weber
This figure shows the co-authorship network connecting the top 25 collaborators of Karsten E. Weber. A scholar is included among the top collaborators of Karsten E. Weber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karsten E. Weber. Karsten E. Weber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Denkert, Carsten, Martin Filipits, Karsten E. Weber, et al.. (2024). Relationship of adaptive subtyping and tumour heterogeneity of treatment response to neoadjuvant therapy in hormone receptor–positive HER2-negative early breast cancer: PENELOPE-B.. Journal of Clinical Oncology. 42(16_suppl). 566–566.
2.
Jurmeister, Philipp, Karsten E. Weber, Sonia L. Villegas, et al.. (2021). DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status. Clinical Epigenetics. 13(1). 184–184.
3.
Karn, Thomas, Karsten E. Weber, Uwe Holtrich, et al.. (2020). 127O Tumour mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Annals of Oncology. 31. S58–S58.
4.
Karn, Thomas, Carsten Denkert, Karsten E. Weber, et al.. (2019). Para-necrotic expression of VEGFA metagene signature identified by single-cell profiling. Annals of Oncology. 30. iii4–iii4.
5.
Noske, Aurelia, Volker Möbus, Karsten E. Weber, et al.. (2019). Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node–positive study. European Journal of Cancer. 114. 76–88.
6.
Witzel, Isabell, Sibylle Loibl, Ralph M. Wirtz, et al.. (2019). Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. British Journal of Cancer. 121(12). 1009–1015.
7.
Loibl, Sibylle, Karsten E. Weber, Jens Huober, et al.. (2018). Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. Clinical Cancer Research. 24(14). 3358–3365.
8.
Stevic, Ines, Volkmar Müller, Karsten E. Weber, et al.. (2018). Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Medicine. 16(1). 179–179.
9.
Villegas, Sonia L., Silvia Darb‐Esfahani, Gϋnter von Minckwitz, et al.. (2017). Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer. Breast Cancer Research and Treatment. 168(1). 179–187.
10.
Loibl, Sibylle, Nicole Pfarr, Karsten E. Weber, et al.. (2017). Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls. Annals of Oncology. 28. i4–i4.
11.
Schouten, Philip C., Karsten E. Weber, Valentina Nekljudova, et al.. (2017). BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial. Breast Cancer Research and Treatment. 166(3). 775–785.
12.
Mackelenbergh, Marion van, Carsten Denkert, Valentina Nekljudova, et al.. (2017). Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Research and Treatment. 167(1). 59–71.
13.
Martín, Miguel, Jan C. Brase, Amparo Ruı́z, et al.. (2016). Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. Breast Cancer Research and Treatment. 156(1). 81–89.
14.
Martín, Miguel, Jan C. Brase, Lourdes Calvo, et al.. (2014). Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Research. 16(2). R38–R38.
15.
Dubsky, Peter, Jan C. Brase, R. Jakesz, et al.. (2013). The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients. British Journal of Cancer. 109(12). 2959–2964.
16.
Dubsky, Peter, Martin Filipits, R. Jakesz, et al.. (2012). EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Annals of Oncology. 24(3). 640–647.
17.
Müller, Berit, Jan C. Brase, Karsten E. Weber, et al.. (2012). Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections. Journal of Clinical Pathology. 65(7). 660–662.
18.
Kronenwett, Ralf, Kerstin Bohmann, Judith Prinzler, et al.. (2012). Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. BMC Cancer. 12(1). 456–456.
19.
Müller, Berit, Ralf Kronenwett, Guido Hennig, et al.. (2011). Quantitative Determination of Estrogen Receptor, Progesterone Receptor, and HER2 mRNA in Formalin-fixed Paraffin-embedded Tissue—A New Option for Predictive Biomarker Assessment in Breast Cancer. Diagnostic Molecular Pathology. 20(1). 1–10.
20.
Wilson, George D., et al.. (1998). Reproducibility of measurements of potential doubling time of tumour cells in the multicentre National Cancer Institute protocol T92-0045. British Journal of Cancer. 79(2). 323–332.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Matthew D. Burstein Breakdown of academic impact, for papers by Zakaria Einbeigi Breakdown of academic impact, for papers by Ida Minchella Breakdown of academic impact, for papers by Farhat Ben Ayed Breakdown of academic impact, for papers by Giorgio Mustacchi Breakdown of academic impact, for papers by Rutger H.T. Koornstra Breakdown of academic impact, for papers by Yidong Zhou Breakdown of academic impact, for papers by Mireia Margelí Vila Breakdown of academic impact, for papers by Gian Luigi Cetto Breakdown of academic impact, for papers by Chiu-Kit Tse